1.Clinical Observation of Modified Xiaoyao Powder Plus Abdominal Needling for Conducting Fire Back to Its Source in Treating Swallowing Dysfunction in Parkinson's Disease
Xiaoming PAN ; Yuyang BAI ; Xiaoqing YANG ; Weiming WAN
Journal of Guangzhou University of Traditional Chinese Medicine 2017;34(4):538-542
Objective To investigate the therapeutic effects of modified Xiaoyao Powder combined with abdominal needling for conducting fire back to its source for the treatment of swallowing dysfunction in Parkinson's disease, and to explore a more effective therapy for swallowing dysfunction in Parkinson's disease. Methods Forty-two Parkinson's disease patients suffering from swallowing dysfunction were divided into treatment group and control group, 21 cases in each group. The patients in both groups received routine swallowing function training. In addition to the training, the treatment group was treated with modified Xiaoyao Powder combined with abdominal needling for conducting fire back to its source, and the control group was given conventional western medicine of Domperidone and Levodopa Benserazide Hydrochloride. After treatment for 3 weeks, we compared the dysphagia scores and effective rate of the two groups. Results (1) All of the patients in the treatment group completed the trial, but 2 cases of the control group dropped out. Therefore, a total of 40 cases completed the trial. (2) The dysphagia scores of the two groups were much improved after treatment (P<0.01 compared with those before treatment) , and the improvement of the treatment group was superior to that of the control group (P < 0.05). (3) After treatment for 3 weeks, the total effective rate of the treatment group was 95.24% and that of the control group was 52 . 63%, and the difference was statistically significant between the two groups(P<0.01).(4) Gastrointestinal reaction occurred in 3 cases(one from the treatment group and 2 from the control group) , but there were no other side effects found in both groups. Conclusion Modified Xiaoyao Powder combined with abdominal needling for conducting fire back to its source is more effective for the treatment of swallowing dysfunction in Parkinson's disease than routine western medicine treatment.
2.Vascular endothelial factor C and E-cadherin relationship with the invasion and metastasis of human gastric cancer
Weiming LIU ; Xuefeng LI ; Jian GUO ; Zhiliang SHI ; Guoqiang ZHOU ; Jian PENG ; Chuandan WAN
Clinical Medicine of China 2016;32(6):502-505
Objective To investigate the expression of vascular endothelial factor C(VEGF-C) and E-cadherin in gastric cancer and explore the relationship between expression of VEGF-C and E-cadherin and the pathogenesis of gastric cancer.Methods Real-time quantitative reverse ranscriptase-polymerase chain rection was applied on 40 cases of gastric cancer and corresponding adjacent noncancerous tissues,in order to detect mRNA expression of VEGF-C and E-cadherin gene.VEGF-C and E-cadherin protein expression in gastric cancer and adjacent normal gastric mucosa were detected by immunohistochemistry.Statistical analysis was carried out to analyze the correlation among VEGF-C,E-cadherin and protein expression with various clinical parameters in these gastric cancer patients.Results The expression of VEGF-C protein in 40 cases of gastric cancer's cancer tissues was 0.461±0.012,significantly higher than that in the adjacent normal tissues(0.036+0.023;t=1.101,P<0.05),but E-cadherin expression was significantly lower than that of the adjacent normal tissues (0.079±0.002 vs.0.321±0.005;t=1.844,P<0.05).There was correlation between VEGF-C mRNA expression with histological grading,TNM staging,lymph node and distant metastasis (t=-1.621,-1.474,-2.378,-1.966,P<0.05).There was correlation between E-cadherin mRNA expression with tumor size,histological grading,TNM stage,there was a significant difference (t=1.875,1.673,1.544,P<0.05).VEGF-C and E-cadherin protein expression was negatively correlated(r=-0.688,P<0.05).Conclusion Up-regulated of VEGF-C gene and decreased expression of E-cadherin may play an important role in the carcinogenesis of gastric cancer
3.Treatment of upper ureteral calculi by an ureteroscopy approach in a low-head lithotomy with right or left lateral tilt
Shunhui YUAN ; Delin YANG ; Zhipeng LI ; Guihua CAO ; Lu YU ; Chunwei YE ; Weiming WAN
China Journal of Endoscopy 2016;22(8):87-89
ObjectiveTo evaluate the methods in treatment of upper urinary calculi in a low-head lithotomy with right or left lateral tilt by an ureteroscopy approach. Methods From September 2009 to May 2015, 110 patients with upper ureteral calculi (after failed ESWL) were underwent holmium laser lithotripsy by a ureteroscopy approach in a low-head lithotomy with right or left lateral tilt. Their clinical data and complications were analyzed retrospectively. Results Surgical effect of patients was satisfied with the success of gravel 91 patients, with a total rate of 82.7 %gravel. Conclusion Low-head lithotomy with right or left lateral tilt is a good body position to perform ureteroscopic lithotripsy for upper ureteral calculi. It is safe and effective.
4. Efficacy and safety of domestic dasatinib as second-line treatment for chronic myeloid leukemia patients in the chronic phase
Yilin CHEN ; Long WANG ; Guolin YAN ; Zhuangzhi YANG ; Zhiping HUANG ; Youshan ZHANG ; Zhe ZHAO ; Chucheng WAN ; Ying BAO ; Hang XIANG ; Hua YIN ; Lifeng CHEN ; Yingyuan XIONG ; Li MENG ; Weiming LI
Chinese Journal of Hematology 2019;40(2):98-104
Objective:
To investigate the efficiency and safety of domestic tyrosine kinase inhibitor (TKI) dasatinib (Yinishu) as second-line treatment for patients with chronic myeloid leukemia in chronic phase (CML-CP).
Methods:
A retrospective analysis of clinical data of CML-CP patients who received domestic dasatinib as second-line treatment in the CML collaborative group hospitals of Hubei province from March 2016 to July 2018 was performed. The optimal response rate, the cumulative complete cytogenetic response (CCyR), the cumulative major molecular responses (MMR), progression free survival (PFS), event free survival (EFS) and adverse effects (AEs) of the patients were assessed at 3, 6 and 12 months of treatment.
Results:
A total of 83 CML-CP patients were enrolled in this study. The median follow-up time was 23 months. The optimal response rates at 3, 6 and 12 months in 83 CML-CP patients treated with dasatinib were 77.5% (54/71), 72.6% (61/75) and 60.7% (51/69), respectively. By the end of follow-up, the cumulative CCyR and MMR rates were 65.5% (55/80) and 57.1% (48/73), respectively. The median time to achieving CCyR and MMR was 3 months. During follow-up time, the PFS rate was 94.0% (79/83) and the EFS rate was 77.4% (65/83). The most common non-hematological AEs of dasatinib were edema (32.5%), rash itching (18.1%) and fatigue (13.3%). The common hematological AEs of dasatinib were thrombocytopenia (31.3%), leukopenia (19.3%) and anemia (6.0%).
Conclusion
Domestic dasatinib was effective and safe as the second-line treatment of CML-CP patients and it can be used as an option for CML-CP patients.